Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn 2006, Issue 3, 2020, Pages

  Appleton, Sarah ^a   Jones, Terry ^a   Poole, Phillippa ^b   Lasserson, Toby J ^c   Adams, Robert ^a   Smith, Brian J ^d   Muhammed, Julia ^d  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c University of Auckland ^*  (United Kingdom)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE METHYL NITRATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; IPRATROPIUM BROMIDE; OXITROPIUM BROMIDE; SALMETEROL;

AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EXERCISE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH STATUS; HEMODYNAMICS; HUMAN; LONG TERM CARE; LUNG FUNCTION; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT PARTICIPATION; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 85087038418     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006101     Document Type: Article

References (67)

1. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 2001; 164:778-84. x-wiley/crsRef/3435031
2. Goodwin B, Cox F, Anderson W, Wisniewski M, Rickard K. Comparison of salmeterol 42uG BID (SLG) versus ipratropium bromide 36 uG q.i.d. vs placebo on disease specific quality of life in COPD patients: reversible or non-reversible to ventolin. In: American Thoracic Society International Conference. 1999. x-wiley/crsRef/3435033
3. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115(4):957-65. x-wiley/crsRef/3435034
4. SLGA4005. A randomized, double-blind, double-dummy, comparative clinical trial of 12-week courses of salmeterol xinafoate versus ipratropium bromide versus placebo (prn ventolin®) in subjects with chronic obstructive pulmonary disease. http://ctr.gsk.co.uk 2005. x-wiley/crsRef/3435035
5. Goodwin B, Cox F, Anderson W, Wisniewski M, Rickard K. Comparison of salmeterol 42uG BID (SLG) versus ipratropium bromide 36 uG q.i.d. vs placebo on disease specific quality of life in COPD patients: reversible or non-reversible to ventolin. In: American Thoracic Society International Conference. 1999. x-wiley/crsRef/3435037
6. Rennard S, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, et al. Use of a long-acting inhaled Beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 2001; 163(5):1087-92. x-wiley/crsRef/3435038
7. SLGA4004. A randomized, double-blind, double-dummy, comparative clinical trial of 12-week courses of salmeterol xinafoate versus ipratropium bromide versus placebo (prn ventolin) in subjects with chronic obstructive pulmonary disease. http://ctr.gsk.co.uk 2005. x-wiley/crsRef/3435039
8. SMS40314. A multicenter, randomized, double-blind, double-dummy, parallel-group, 8-week comparison of salmeterol xinafoate versus ipratropium bromide versus salmeterol xinafoate plus ipratropium bromide versus placebo in subjects with chronic obstructive pulmonary disease. http://ctr.gsk.co.uk 2005. x-wiley/crsRef/3435041
9. SMS40315. A multicenter, randomized, double-blind, double-dummy, parallel group, 8-week comparison of salmeterol xinafoate versus ipratropium bromide versus salmeterol xinafoate plus ipratropium bromide versus placebo in subjects with chronic obstructive pulmonary disease. http://ctr.gsk.co.uk 2005. x-wiley/crsRef/3435043
10. Stahl E, Wadbo M, Bengtsson T, Strom K, Lofdahl C-G. Health-related quality of life, symptoms, exercise capacity and lung function during treatment for moderate to severe COPD. Journal of Drug Assessment 2002; 5:81-94. x-wiley/crsRef/3435045
11. Wadbo M, Lofdahl CG, Larsson K, Skoogh BE, Tornling G, Arwestrom E, et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. European Respiratory Journal 2002; 20(5):1138-46. x-wiley/crsRef/3435046
12. Rutten-van Molken M, Roos B, van Noord JA. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial. Thorax 1999; 54:995-1003. x-wiley/crsRef/3435048
13. SLGF55. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. http:ctr.gsk.co.uk 2005. x-wiley/crsRef/3435049
14. van Noord JA, de Munck DR, Bantje TA, Hop WCJ, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. European Respiratory Journal 2000; 15:878-85. x-wiley/crsRef/3435050
15. Bauer VP, Kummer F. The action of a tropic acid ester on bronchospasm:A double-blind study [Zur wirkung eines tropasaure-esters auf den bronchospasmus]. Wiener Klinische Wochenschrift 1975; 87(4):132-6. x-wiley/crsRef/3435052
16. Brown IG, Chan CS, Kelly CA, Dent AG, Zimmerman PV. Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation. Thorax 1984; 39:272-6. x-wiley/crsRef/3435054
17. Dejaegher Ph, Demedts M, Rochette F, Van der Veken J. Effects of 40ug and 400ug of ipratropium bromide in obstructive lung disease. Acta Clinica Belgica 1984; 39(3):136-40. x-wiley/crsRef/3435056
18. Disse B, Speck GA, Rominger KL, Witek TJ, Hammer R. Tiotropium (SPIRIVA): Mechanistical considerations and clinical profile in obstructive lung disease. Life Sciences 1999; 64(6/7):457-64. x-wiley/crsRef/3435058
19. Heimer D, Brami JL, Liberman D, Bark H. Comparison of a B2 adrenergic agonist and an anticholinergic agent given by sequential inhalation in patients with severe chronic obstructive pulmonary disease. Israel Journal of Medical Science 1991; 27:307-10. x-wiley/crsRef/3435060
20. Banos Hidalgo P, Ramos Martos A, Cabrera Moreno R, Luque Leal J, Palcios Giner YA. Comparacion en estudio doble ciego de la asociacion de un aerosol de salbutamol y bromuro de ipratropio y de su efecto individual en bronquitis cronica y asma bronquial. Revista Clinica Espanola 1983; 171(4):265-8. x-wiley/crsRef/3435062
21. Kheir A, Ying Y, Hannhart B, Duvivier C, Peslin R, Polu JM. Comparison de l'effet bronchodilatateur at du site d'action du fenoterol et de l'ipratropium chez bronchiteux chroniques obstructifs [A comparison of the bronchodilator effect and the site of action of fenoterol and of ipratropium in bronchitis with airflow obstruction]. Revue des Maladies Respiratoires 1993; 10:9-15. x-wiley/crsRef/3435064
22. Khristoliubova EI, Volkova LI, Shcherbakova IV. Long-term atrovent treatment of chronic obstructive bronchitis. Klinicheskaia Meditsina (Mosk) 1999; 77(12):51-2. x-wiley/crsRef/3435066
23. Lees AW, Allan GW, Smith J. Nebulised ipratropium bromide and salbutamol in chronic bronchitis. British Journal of Clinical Practise 1980; 34(11-12):340-2. x-wiley/crsRef/3435068
24. Leitch AG, Hopkins JM, Ellis DA, Merchant S, McHardy GJR. The effect of aerosol ipratropium bromide and salbutamol on exercise tolerance in chronic bronchitis. Thorax 1978; 33:711-3. x-wiley/crsRef/3435070
25. Lien J Th. Clinical comparison of Atrovent and placebo in patients with chronic obstructive lung diseases [Klinisk sammenligning av Atrovent og placebo hos pasienter med kronisk ostruktiv lungesykdom]. Tidsskr Nor Loegeforen 1980; 100(19-21):1193-5. x-wiley/crsRef/3435072
26. Matera MG, Caputi M, Cazzola M. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respiratory Medicine 1996; 90:497-9. x-wiley/crsRef/3435074
27. Nardini S. Inhaled antimuscarinic agents and COPD. Monaldi Archives for Chest Disease 1996; 51(1):52-3. x-wiley/crsRef/3435076
28. Nishimura K, Koyama H, Izumi T. A comparison of bronchodilating drugs for the treatment of stable COPD. Nihon Hyobu Shikkan Gakkai Zasshi 1992; 30(5):835-43. x-wiley/crsRef/3435078
29. Petro W, Nakhosteen JA, Konietzko N. Bronchodilator effect of a combination of a beta-adrenergic agonist and a cholinergic antagonist [Broncholyse unter kombinierter anwendung von Beta-adrenergen agonisten und cholinergen antagonisten]. Praxis der Pneumologie vereinigt mit Der Tuberkuloserarzt 1981; 35:779-82. x-wiley/crsRef/3435080
30. Pierce RJ, Holmes PW, Campbell AH. Use of ipratropium bromide in pateints with severe airways obstruction. Australian and New Zealand Journal of Medicine 1982; 12:38-43. x-wiley/crsRef/3435082
31. Shmelev EI, Khmel'kova NG, Nonikov DV, Melent'eva EM, Abubikirov AF, Makarova VL, et al. Experience in long-term use of berodual in the treatment of patients with chronic obstructive bronchitis. Terapevticheskii Arkhiv 1999; 71(3):22-4. x-wiley/crsRef/3435084
32. Simanenkov VI, Il'iashevich IG, Liparteliani BG, Ledovaia AV. Long-term atrovent treatment of chronic obstructive bronchitis [Dlitel'noe lechenie atroventom pri khronicheskom obstruktivnom bronkhite]. Terapevticheskii Arkhiv 1998; 70(9):77-9. x-wiley/crsRef/3435086
33. Tang OT, Flatley M. A comparison of effects of inhaling a combined preparation of fenoterol with ipratropium bromide (Duovent) with those of fenoterol and salbutamol. Postgraduate Medical Journal 1984; 60:24-7. x-wiley/crsRef/3435088
34. Anthonisen NR, Wright EC. Bronchodilator response in chronic obstructive pulmonary disease. American Review of Respiratory Disease 1986; 133:814-9.
35. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study. JAMA 1994; 272:1497-505.
36. Appleton S, Poole P, Smith B, Cates C, Veale A, Bara A. Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation (Cochrane review). The Cochrane Database of Systematic Reviews 2001, Issue 4.
37. Appleton S, Jones T, Poole P, Pilotto L, Adams R, Lasserson TJ, et al. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease (Cochrane review). Cochrane Database of Systematic Reviews 2006, Issue 2.
38. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. European Respiratory Journal 2004; 23:932-46.
39. Barnes PJ. Theoretical aspects of anticholinergic treatment. In: Gross NJ, editors(s). Anticholinergic therapy in obstructive airways disease. London: Franlkin Scientific Publications, 1993.
40. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease (Cochrane review). The Cochrane Database of Systematic Reviews 2005, Issue 2.
41. Belman M, Botnick W, Shin J. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 1996; 153:967-75.
42. Blosser SA, Maxwell SL, Reeves-Hoche MK, Localio AR, Zwillich CW. Is an anti-cholinergic agent superior to a beta-2 agonist in improving dyspnea and exercise limitation in COPD? Chest 1995; 108:730-5.
43. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). European Respiratory Journal 1997; 10:815-21.
44. British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52(Suppl 5):S2-S28.
45. Calverly PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58:659-64.
46. Chapman KR. Clinical implications of anticholinergic bronchodilator therapy in COPD. Research & Clinical Forums 1991; 13(2):43-50.
47. Commonwealth of Australia. Schedule of Pharmaceutical Benefits Effective from May 2001; GENERAL Respiratory system. http://www.health.gov.au/pbs/scripts/dispgp.cfm 2000.
48. D'Urzo A, De Salvo M, Ramirez-Rivera A, Almeida J, Sichletidis L, Rapatz G, Kottakis J. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: A 3 week, randomized, double-blind, with-in patient, multicentre study. Chest 2001; 119:1347-56.
49. Ferguson G. Recommendations for the management of COPD. Chest 2000; 117(2 Suppl):23s-28s.
50. National Heart, Lung, and Blood Institute. Global Initiative on Obstructive Lung Disease (GOLD) Pocket Guide (updated 2003). www.goldcopd.com [accessed 16/02/04].
51. National Heart, Lung, and Blood Institute. Global Initiative for Chronic Obstructive Pulmonary Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2004). www.goldcopd.com [accessed 21/03/05].
52. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996; 17(1):1-12.
53. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 2002; 166:1084-91.
54. Matera MG, Cazzola M, Vinciguerraaa A, et al. Comparison of hte bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulmonary Pharmacology 1995; 8:267-71.
55. National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease. National clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59(Suppl I):1-232.
56. Nisar M, Earis JE, Pearson MG, Calverly PMA. Acute bronchodilator trials in chronic obstructive pulmonary disease. American Review of Respiratory Disease 1992; 146:555-9.
57. O'Donnell D, Bertley J, Chau L, Webb K. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiological mechanisms. American Journal of Respiratory & Critical Care Medicine 1997; 155:109-15.
58. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation and endurance during exercise in chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 1998; 158:1557-65.
59. O' Donnell D, Lam M, Webb K. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 1999; 160:542-9.
60. O' Donnell D. Assessment of bronchodilator efficacy in symptomatic COPD. Is spirometry useful? Chest 2000; 117(2 Suppl):42s-47s.
61. Pauwels R. National and international guidelines for COPD: The need for evidence. Chest 2000; 117(2 Suppl):20s-22s.
62. Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121:1058-69.
63. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal 2004; 23(5):698-702.
64. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123:1441-49.
65. Ullah MI, Newman GB, Saunders KB. Influence of age in response to ipratropium and salbutamol in asthma. Thorax 1981; 36:523-9.
66. Ulrik C. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre, randomised, double blind, placebo controlled, cross over study. Thorax 1995; 50:750-4.
67. van Weel C. Combining nebulised ipratropium and albuterol improved FEV1 but did not improve symptoms or quality of life in COPD. Evidence-Based Medicine 1998:120.